SpringWorks Therapeutics, Inc. Common Stock
SWTX Real Time Price USDRecent trades of SWTX by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by SWTX's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Treatments with nirogacestat Nov. 12, 2024
-
Patent Title: Synthesis of nirogacestat Oct. 08, 2024
-
Patent Title: Dispersible formulations of n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benazmide and uses thereof Sep. 17, 2024
-
Patent Title: Treatments with nirogacestat Jul. 16, 2024
-
Patent Title: 2-pyrazole anilines and related analogs for inhibiting yap/taz-tead Jul. 09, 2024
-
Patent Title: Dosage forms of mirdametinib Jul. 09, 2024
-
Patent Title: Treatments with nirogacestat Jun. 18, 2024
-
Patent Title: Treatments with nirogacestat Jun. 18, 2024
-
Patent Title: Treatment of neurofibromatosis type 1 (nf1) associated plexiform neurofibromas (pn) in pediatric patients with mirdametinib Jun. 18, 2024
-
Patent Title: Treatments with nirogacestat Apr. 16, 2024
-
Patent Title: Treatments with nirogacestat Apr. 09, 2024
-
Patent Title: Treatments with nirogacestat Mar. 26, 2024
-
Patent Title: Treatments with nirogacestat Mar. 12, 2024
-
Patent Title: Treatments with nirogacestat Mar. 12, 2024
-
Patent Title: Crystalline solids of mek inhibitor n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof Jan. 30, 2024
-
Patent Title: Mirdametinib treatment Jan. 30, 2024
-
Patent Title: Treatments with nirogacestat Jan. 16, 2024
-
Patent Title: Chlorinated tetralin compounds and pharmaceutical compositions Dec. 19, 2023
-
Patent Title: Mirdametinib treatment Dec. 12, 2023
-
Patent Title: Treatment of neurofibromatosis type 1 (nf1) associated plexiform neurofibromas (pn) in pediatric patients with mirdametinib Nov. 21, 2023
-
Patent Title: Chlorinated tetralin compounds and pharmaceutical compositions Nov. 07, 2023
-
Patent Title: Mirdametinib treatment Nov. 07, 2023
-
Patent Title: Non-linear dosing of mirdametinib Nov. 07, 2023
-
Patent Title: Fluorinated phenylamino compounds and pharmaceutical compositions Oct. 10, 2023
-
Patent Title: Dispersible formulations of n-((r)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof Feb. 07, 2023
-
Patent Title: Solids of mek inhibitor n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide and uses thereof Aug. 30, 2022
-
Patent Title: Crystalline solids of mek inhibitor n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof Aug. 10, 2021
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of SWTX in WallStreetBets Daily Discussion
Recent insights relating to SWTX
Recent picks made for SWTX stock on CNBC
ETFs with the largest estimated holdings in SWTX
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view SWTX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.